TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7697902

Group type: EXPERIMENTAL
Intervention: Misoprostol (200 micrograms qid)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ranitidine (150 mg bid)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sucralfate (1 g qid)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Omeprazole
Number of subjects: 0

Group type: COMPARATOR
Intervention: Mucosal-coating compounds
Number of subjects: 0

Group type: COMPARATOR
Intervention: Gastric antisecretory drugs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Misoprostol
Number of subjects: 0
Study: 2761586

Group type: EXPERIMENTAL
Intervention: Clomipramine
Number of subjects: 13

Group type: COMPARATOR
Intervention: Desipramine
Number of subjects: 13
Study: 241932

Group type: EXPERIMENTAL
Intervention: Betaket (combination of beta-receptor blocker and isosorbide dinitrate)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Betadrenol (beta-receptor blocker)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Isoket (isosorbide dinitrate preparation)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 29584924

Group type: EXPERIMENTAL
Intervention: Breast milk with coconut oil
Number of subjects: 60

Group type: COMPARATOR
Intervention: Breast milk alone
Number of subjects: 60
Study: 27027462

Group type: EXPERIMENTAL
Intervention: Remifentanil
Number of subjects: 34

Group type: COMPARATOR
Intervention: Morphine
Number of subjects: 34
Study: 24917586

Group type: EXPERIMENTAL
Intervention: STEPS walking intervention offered during rehabilitation
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: STEPS walking intervention offered after rehabilitation
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: STEPS walking intervention
Number of subjects: 26

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 26
Study: 22921680

Group type: EXPERIMENTAL
Intervention: Antiplatelet therapy (n=72), administered 24 hours after rt-PA for 10 days
Number of subjects: 146

Group type: COMPARATOR
Intervention: Non-antiplatelet therapy (n=74), received no antiplatelet therapy
Number of subjects: 146
Study: 20142732

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 18503929

Group type: EXPERIMENTAL
Intervention: Iloprost (group A, n = 23)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Nitric oxide (iNO) (group B, n = 23)
Number of subjects: 46
Study: 15920051

Group type: EXPERIMENTAL
Intervention: Oral insulin spray (20 puffs)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Oral insulin spray (5, 10, and 20 puffs)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Oral insulin spray
Number of subjects: 7

Group type: COMPARATOR
Intervention: Subcutaneous regular insulin
Number of subjects: 7
Study: 12735483

Group type: EXPERIMENTAL
Intervention: Magnesium supplementation for two months
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 9700963

Group type: COMPARATOR
Intervention: 0 drops of corn syrup solution
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: 1 drop of corn syrup solution
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: 2 drops of corn syrup solution
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: 3 drops of corn syrup solution
Number of subjects: 19
Study: 1818544

Group type: EXPERIMENTAL
Intervention: Cyclosporin and Methotrexate (CM)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Cyclosporin, Methotrexate and Prednisolone (CMP)
Number of subjects: 41
Study: 6892479

Group type: EXPERIMENTAL
Intervention: Lysine‐8‐vasopressin (LVP) 5 I.U. administered intranasally daily for 5 days
Number of subjects: 21

Group type: COMPARATOR
Intervention: NaCl administered intranasally daily for 5 days (control group)
Number of subjects: 21
Study: 31957638

Group type: EXPERIMENTAL
Intervention: Yoga
Number of subjects: 41

Group type: COMPARATOR
Intervention: Educational Film (EF)
Number of subjects: 41
Study: 30739911

Group type: EXPERIMENTAL
Intervention: Bevacizumab plus pemetrexed–cisplatin triplet
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: MST1 inactivation
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: YAP silencing in MST1-depleted mesothelial cell lines
Number of subjects: 223
Study: 27845156

Group type: EXPERIMENTAL
Intervention: Alpha/theta (A/T) training (neurofeedback group, NFG)
Number of subjects: 50
Study: 27806897

Group type: EXPERIMENTAL
Intervention: Absorb bioresorbable scaffold
Number of subjects: 501

Group type: COMPARATOR
Intervention: Xience metallic stent
Number of subjects: 501
Study: 24613543

Group type: EXPERIMENTAL
Intervention: CRT + nimotuzumab
Number of subjects: 92

Group type: COMPARATOR
Intervention: CRT
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: RT + nimotuzumab
Number of subjects: 92

Group type: COMPARATOR
Intervention: RT
Number of subjects: 92
Study: 22384088

Group type: EXPERIMENTAL
Intervention: Single bolus injection of erythropoietin, acute effects studied for 1-10 hours.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prolonged administration of recombinant human erythropoietin (rHuEpo) for 16 days.
Number of subjects: 0
Study: 20829661

Group type: EXPERIMENTAL
Intervention: Wound cleansing solution containing polihexanide and betaine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 18251141

Group type: EXPERIMENTAL
Intervention: Minilaparotomy
Number of subjects: 46

Group type: COMPARATOR
Intervention: Conventional
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 46
Study: 15734253

Group type: EXPERIMENTAL
Intervention: Tourniquet (group A)
Number of subjects: 20

Group type: COMPARATOR
Intervention: No tourniquet (group B)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both groups (A and B)
Number of subjects: 20
Study: 11489001

Group type: EXPERIMENTAL
Intervention: Epirubicin in combination with carboplatin and paclitaxel (ET-Carbo)
Number of subjects: 1281

Group type: COMPARATOR
Intervention: Carboplatin and paclitaxel (Carbo-T)
Number of subjects: 1281
Study: 9832904

Group type: EXPERIMENTAL
Intervention: Therapeutic play (interactive puppet show)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Routine care (control group)
Number of subjects: 50
Study: 7595261

Group type: EXPERIMENTAL
Intervention: Oral metronidazole 500 mg twice daily for 1 week
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Metronidazole vaginal gel 0.75% 5 g twice daily for 5 days
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Clindamycin vaginal cream 2% 5 g once daily for 7 days
Number of subjects: 101
Study: 2292207

Group type: EXPERIMENTAL
Intervention: Ceftriaxone 1 g as a single preoperative dose
Number of subjects: 200

Group type: COMPARATOR
Intervention: Cefotaxime 1 g preoperative dose plus 9 postoperative doses every 8 h for 3 days
Number of subjects: 200
Study: 7407745

Group type: EXPERIMENTAL
Intervention: L-tryptophan (6 grams daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (6 grams daily)
Number of subjects: 0
Study: 31698965

Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 0

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 0
Study: 31551225

Group type: EXPERIMENTAL
Intervention: Mucopolysaccharide polysulfate ointment combined with desonide ointment
Number of subjects: 180

Group type: COMPARATOR
Intervention: Desonide ointment only
Number of subjects: 180
Study: 28125598

Group type: EXPERIMENTAL
Intervention: Corticosteroid therapy
Number of subjects: 7

Group type: COMPARATOR
Intervention: No corticosteroid therapy
Number of subjects: 7
Study: 29046015

Group type: EXPERIMENTAL
Intervention: Magnesium sulfate (30 mg/kg bolus dose and infusion at 10 mg/kg/h)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Normal saline (control group)
Number of subjects: 100
Study: 24631042

Group type: EXPERIMENTAL
Intervention: A manihot (huangkui capsule), 2.5 g, 3 times per day
Number of subjects: 417

Group type: COMPARATOR
Intervention: Losartan potassium, 50 mg/d
Number of subjects: 417

Group type: EXPERIMENTAL
Intervention: Combined treatment (A manihot + losartan)
Number of subjects: 417
Study: 23115404

Group type: EXPERIMENTAL
Intervention: Nightly zolpidem, 10 mg (5 mg for patients > 60 yrs)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 91
Study: 19569018

Group type: EXPERIMENTAL
Intervention: Oral phosphate (Pi) load (100 mmol) in NTS group
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Oral phosphate (Pi) load (100 mmol) in CNT group
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Oral phosphate (Pi) load (100 mmol) in NTS and CNT groups
Number of subjects: 84

Group type: COMPARATOR
Intervention: NTS and CNT groups compared to GK
Number of subjects: 84
Study: 17563571

Group type: EXPERIMENTAL
Intervention: Estimated GFR (MDRD formula)
Number of subjects: 15245

Group type: EXPERIMENTAL
Intervention: Estimated creatinine clearance (Cockcroft-Gault)
Number of subjects: 15245
Study: 15109973

Group type: EXPERIMENTAL
Intervention: Pain group (n = 54) - received painful electrocutaneous stimuli
Number of subjects: 107

Group type: COMPARATOR
Intervention: Control group (n = 53) - received non-painful vibrotactile targets
Number of subjects: 107
Study: 11473947

Group type: EXPERIMENTAL
Intervention: GnRH antagonist (ganirelix) during ovarian stimulation for IVF or ICSI
Number of subjects: 333
Study: 9459533

Group type: COMPARATOR
Intervention: 0900 hours
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: 1400 hours
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: 1800 hours
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: 0900 hours to 1800 hours
Number of subjects: 23
Study: 8065723

Group type: EXPERIMENTAL
Intervention: 0.05% clobetasol propionate ointment in orabase
Number of subjects: 55

Group type: COMPARATOR
Intervention: 0.05% fluocinonide ointment in orabase
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Both medications (clobetasol propionate and fluocinonide)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Candidiasis observed in patients
Number of subjects: 55
Study: 2115186

Group type: EXPERIMENTAL
Intervention: PGI2 (6 ng/kg/min over 8 hours daily for 5 consecutive days)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 108
Study: 76841

Group type: EXPERIMENTAL
Intervention: Treatment
Number of subjects: 208

Group type: COMPARATOR
Intervention: Control (Untreated)
Number of subjects: 208

Group type: COMPARATOR
Intervention: Control (Previously unscarred kidneys)
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Progression of re‐existing kidney scars
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: High-risk group
Number of subjects: 208
Study: 31829267

Group type: EXPERIMENTAL
Intervention: Maternal physical activity optimism at 4 months
Number of subjects: 259

Group type: EXPERIMENTAL
Intervention: Home physical activity equipment at 9 months
Number of subjects: 259

Group type: EXPERIMENTAL
Intervention: Time outdoors - middle tertile at 9 months
Number of subjects: 259

Group type: EXPERIMENTAL
Intervention: Time outdoors - highest tertile at 9 months
Number of subjects: 259

Group type: EXPERIMENTAL
Intervention: Time free to move about - highest tertile at 19 months
Number of subjects: 259

Group type: EXPERIMENTAL
Intervention: Time with older children - middle tertile at 19 months
Number of subjects: 259

Group type: EXPERIMENTAL
Intervention: Time with older children - highest tertile at 3.5 years
Number of subjects: 259

Group type: EXPERIMENTAL
Intervention: Mothers' own physical activity at 9 months
Number of subjects: 259

Group type: EXPERIMENTAL
Intervention: Time active with mum - highest tertile at 3.5 years
Number of subjects: 259

Group type: EXPERIMENTAL
Intervention: Time with older children - highest tertile at 4 months
Number of subjects: 259

Group type: EXPERIMENTAL
Intervention: Time free to move about - middle tertile at 19 months
Number of subjects: 259

Group type: EXPERIMENTAL
Intervention: More home equipment at 9 months
Number of subjects: 259

Group type: EXPERIMENTAL
Intervention: More home equipment at 3.5 years
Number of subjects: 259

Group type: EXPERIMENTAL
Intervention: Maternal physical activity knowledge at 3.5 years
Number of subjects: 259
Study: 28917370

Group type: EXPERIMENTAL
Intervention: Osmanthus fragrans oil
Number of subjects: 361

Group type: EXPERIMENTAL
Intervention: Grapefruit oil
Number of subjects: 361

Group type: COMPARATOR
Intervention: Control group (no inhalation)
Number of subjects: 361

Group type: COMPARATOR
Intervention: Vehicle group (essential-oil-less vapor)
Number of subjects: 361

Group type: EXPERIMENTAL
Intervention: Lavender oil
Number of subjects: 361
Study: 25929192

Group type: EXPERIMENTAL
Intervention: ALN/D5600 (70 mg/vitamin D3 5600 IU) once weekly
Number of subjects: 219

Group type: COMPARATOR
Intervention: Calcitriol (0.25 μg/day)
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: ALN/D5600
Number of subjects: 219

Group type: COMPARATOR
Intervention: Calcitriol
Number of subjects: 219
Study: 23643501

Group type: EXPERIMENTAL
Intervention: RTMCE
Number of subjects: 2014

Group type: COMPARATOR
Intervention: CSE
Number of subjects: 2014
Study: 20692843

Group type: EXPERIMENTAL
Intervention: Arthrocentesis combined with splint therapy
Number of subjects: 80

Group type: COMPARATOR
Intervention: Rest therapy (restricting mouth opening, analgesic therapy)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Splint therapy
Number of subjects: 80

Group type: COMPARATOR
Intervention: Arthrocentesis of the upper joint space
Number of subjects: 80
Study: 19255014

Group type: EXPERIMENTAL
Intervention: Safe Environment for Every Kid (SEEK) model of pediatric primary care
Number of subjects: 558

Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 558
Study: 16899830

Group type: EXPERIMENTAL
Intervention: Nicotine sublingual tablet
Number of subjects: 370

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 370
Study: 15571272

Group type: EXPERIMENTAL
Intervention: Rasburicase (recombinant urate oxidase)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Allopurinol (standard treatment)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Urate oxidase (non-recombinant form)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rasburicase
Number of subjects: 0
Study: 11391695

Group type: EXPERIMENTAL
Intervention: Bayesian model selection methodology applied to survival analysis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bayesian model selection methodology
Number of subjects: 0
Study: 9783530

Group type: EXPERIMENTAL
Intervention: Trifazid (fixed-dose combination of rifampicin, isoniazid, and pyrazinamide)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Free combinations of rifampicin, isoniazid, and pyrazinamide
Number of subjects: 16
Study: 7841973

Group type: EXPERIMENTAL
Intervention: Broxaterol (400 micrograms)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Salbutamol (400 micrograms)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Cardiopulmonary exercise test (CPX)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 12
Study: 3180489

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (HCTZ) 6.25 mg
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (HCTZ) 12.5 mg
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (HCTZ) 25 mg
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (HCTZ) 50 mg
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 5309530

Group type: EXPERIMENTAL
Intervention: ID-Jet 1 vaccine (10(7.0) TCID(50)/ml)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: ID-Jet 1a vaccine (10(6.3) TCID(50)/ml)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: ID-Jet 2 vaccine (10(6.0) TCID(50)/ml)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Standard multiple-pressure technique
Number of subjects: 140
Study: 31154945

Group type: EXPERIMENTAL
Intervention: Endovascular therapy (ESCAPE trial)
Number of subjects: 286

Group type: EXPERIMENTAL
Intervention: Endovascular therapy (Quality Improvement and Clinical Research patients)
Number of subjects: 286

Group type: COMPARATOR
Intervention: Control (ESCAPE trial)
Number of subjects: 286

Group type: COMPARATOR
Intervention: Usual care (2016/2017 fiscal year)
Number of subjects: 286
Study: 27465661

Group type: EXPERIMENTAL
Intervention: Rationale for SSB price increase as a user fee, effort to reduce obesity, strategy to offset health-care costs, or to protect children
Number of subjects: 494

Group type: EXPERIMENTAL
Intervention: Messages describing the price increase as a user fee or tax
Number of subjects: 494
Study: 25433572

Group type: EXPERIMENTAL
Intervention: Epidural bupivacaine 0.125% with fentanyl 2 μg/mL at 37°C
Number of subjects: 54

Group type: COMPARATOR
Intervention: Epidural bupivacaine 0.125% with fentanyl 2 μg/mL at 20°C
Number of subjects: 54
Study: 23228072

Group type: EXPERIMENTAL
Intervention: Tall Man lettering, covered decimal points, avoiding trailing zeros with decimal units
Number of subjects: 3000

Group type: EXPERIMENTAL
Intervention: Nurse duty duration
Number of subjects: 3000

Group type: COMPARATOR
Intervention: Transcription error rates for inpatient medications
Number of subjects: 3000

Group type: COMPARATOR
Intervention: Transcription error rates for discharge patient medications
Number of subjects: 3000

Group type: COMPARATOR
Intervention: Error rate for labels of dispensed items
Number of subjects: 3000
Study: 21889702

Group type: EXPERIMENTAL
Intervention: Endurant Stent Graft System
Number of subjects: 150
Study: 18771605

Group type: EXPERIMENTAL
Intervention: Ketamine (subanaesthetic doses)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Thiopental (subanaesthetic doses)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 24
Study: 16673208

Group type: EXPERIMENTAL
Intervention: Morning insulin glargine plus morning glimepiride (2, 3 or 4 mg)
Number of subjects: 624

Group type: COMPARATOR
Intervention: Bedtime insulin glargine plus morning glimepiride (2, 3 or 4 mg)
Number of subjects: 624
Study: 15194375

Group type: EXPERIMENTAL
Intervention: Daclizumab 1 mg/kg/dose every 14 days for five doses (group I, n = 107)
Number of subjects: 297

Group type: EXPERIMENTAL
Intervention: Daclizumab 2 mg/kg/dose every 14 days for two doses (group II, n = 112)
Number of subjects: 297

Group type: COMPARATOR
Intervention: No-antibody induction (group III, n = 78)
Number of subjects: 297
Study: 11212085

Group type: EXPERIMENTAL
Intervention: Spiroflor SRL gel (SRL)
Number of subjects: 161

Group type: COMPARATOR
Intervention: Cremor Capsici Compositus FNA (CCC)
Number of subjects: 161
Study: 9415947

Group type: EXPERIMENTAL
Intervention: Sleep Deprivation (SD)
Number of subjects: 9

Group type: COMPARATOR
Intervention: No Sleep Deprivation (NSD)
Number of subjects: 9
Study: 8280513

Group type: EXPERIMENTAL
Intervention: General practitioners' clinical decision to give thrombolytic therapy
Number of subjects: 137

Group type: COMPARATOR
Intervention: Electrocardiograph (ECG)
Number of subjects: 137
Study: 2943192

Group type: EXPERIMENTAL
Intervention: Midazolam, 0.2 mg/kg
Number of subjects: 31

Group type: COMPARATOR
Intervention: Thiopental, 3.5 mg/kg
Number of subjects: 31
Study: 31753727

Group type: EXPERIMENTAL
Intervention: Ramucirumab plus docetaxel
Number of subjects: 530

Group type: COMPARATOR
Intervention: Placebo plus docetaxel
Number of subjects: 530
Study: 29496242

Group type: EXPERIMENTAL
Intervention: Topical TXA (1 g)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Intravenous TXA (1 g)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (no TXA)
Number of subjects: 90
Study: 27073205

Group type: EXPERIMENTAL
Intervention: Ranibizumab
Number of subjects: 610

Group type: COMPARATOR
Intervention: Bevacizumab
Number of subjects: 610
Study: 24942531

Group type: EXPERIMENTAL
Intervention: Baseline physical inactivity
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Men's physical inactivity
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Women's physical inactivity
Number of subjects: 0
Study: 22619612

Group type: EXPERIMENTAL
Intervention: Hyperbaric levobupivacaine 0.42%
Number of subjects: 20

Group type: COMPARATOR
Intervention: Isobaric levobupivacaine 0.42%
Number of subjects: 20
Study: 20850828

Group type: EXPERIMENTAL
Intervention: Holmium laser ablation
Number of subjects: 109

Group type: COMPARATOR
Intervention: Photoselective vaporization
Number of subjects: 109
Study: 18795687

Group type: EXPERIMENTAL
Intervention: Esomeprazole
Number of subjects: 28
Study: 15813757

Group type: EXPERIMENTAL
Intervention: Web-based learning management system
Number of subjects: 66
Study: 12919710

Group type: EXPERIMENTAL
Intervention: Oral alendronate (ALN)
Number of subjects: 306
Study: 10820298

Group type: EXPERIMENTAL
Intervention: Rola Stretcher
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: True Back II
Number of subjects: 12

Group type: COMPARATOR
Intervention: Supine rest
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Firm foam block
Number of subjects: 12
Study: 9004094

Group type: EXPERIMENTAL
Intervention: ACE-inhibitor benazepril
Number of subjects: 0
Study: 1804654

Group type: EXPERIMENTAL
Intervention: 40 mg/kg sodium benzoate
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 80 mg/kg sodium benzoate
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 160 mg/kg sodium benzoate
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 80 to 160 mg/kg sodium benzoate
Number of subjects: 6
Study: 6383991

Group type: EXPERIMENTAL
Intervention: Ceruletide (2 ng/kg/min. i.v.)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Neostigmin (3 x 0.5 mg/die)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Ceruletide
Number of subjects: 60

Group type: COMPARATOR
Intervention: Neostigmin
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Ceruletide and Neostigmin
Number of subjects: 60
Study: 30832624

Group type: EXPERIMENTAL
Intervention: Group-based model of ECD intervention
Number of subjects: 1200

Group type: EXPERIMENTAL
Intervention: Mixed model combining group sessions with personalized home visits
Number of subjects: 1200

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 1200

Group type: EXPERIMENTAL
Intervention: Treatment arm with quarterly booster visits for 6 months
Number of subjects: 1200
Study: 30001746

Group type: EXPERIMENTAL
Intervention: Lotilaner (Credelio™)
Number of subjects: 169

Group type: COMPARATOR
Intervention: Fipronil
Number of subjects: 169
Study: 26702455

Group type: EXPERIMENTAL
Intervention: Intranasal atomised dexmedetomidine (DEX) 2 μg/kg
Number of subjects: 100

Group type: COMPARATOR
Intervention: Saline (control group)
Number of subjects: 100
Study: 24581948

Group type: EXPERIMENTAL
Intervention: Noradrenaline infusion (14 patients)
Number of subjects: 67

Group type: COMPARATOR
Intervention: No catecholamines (53 patients)
Number of subjects: 67